- Home
- KRG vs TFX Comparison
KRG vs TFX Comparison
Compare KRG & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRG | TFX |
|---|---|---|
| Founded | 1971 | 1943 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.6B |
| IPO Year | 2004 | 1994 |
Fundamental Metrics
Financial Performance| Metric | KRG | TFX |
|---|---|---|
| Price | $25.38 | $107.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 9 |
| Target Price | $25.60 | ★ $140.25 |
| AVG Volume (30 Days) | ★ 1.8M | 866.0K |
| Earning Date | 05-20-2026 | 05-27-2026 |
| Dividend Yield | ★ 4.58% | 1.26% |
| EPS Growth | ★ 6750.00 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | $844,365,000.00 | ★ $1,992,713,000.00 |
| Revenue This Year | N/A | $46.78 |
| Revenue Next Year | $3.27 | $3.86 |
| P/E Ratio | $18.51 | ★ N/A |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $18.52 | $100.18 |
| 52 Week High | $26.38 | $143.32 |
Technical Indicators
Market Signals| Indicator | KRG | TFX |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 40.94 |
| Support Level | $21.95 | $102.03 |
| Resistance Level | $26.38 | $108.01 |
| Average True Range (ATR) | 0.40 | 4.37 |
| MACD | -0.12 | -0.95 |
| Stochastic Oscillator | 9.30 | 0.93 |
Price Performance
Historical ComparisonAbout KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.